Help Ensure the Safe Use of Secondary Hyperparathyroid Meds

The new med etelcalcetide (Parsabiv, PAR-sah-biv) will raise questions about treating hyperparathyroidism in dialysis patients.

Hyperphosphatemia and low vitamin D in renal patients leads to hypocalcemia...which stimulates parathyroid hormone (PTH) release.

This is why the first steps in treating patients with elevated PTH are to control high phosphate and treat vitamin D deficiency.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals